All In Biotech

NDA 017768 · Molnlycke Hlth

Hibiclens

Chlorhexidine Gluconate · Topical

Priority review

Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Sep 17, 1976

Approved uses

2

Original approval plus efficacy supplements

Registered trials

551

112 Phase 3, 30 recruiting

FAERS reports

8,186

6,794 serious, 2,730 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 23, 2024.

Uses antimicrobial skin cleanser helps reduce bacteria that potentially can cause disease for skin wound and general skin cleansing surgical hand scrub healthcare personnel handwash

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 1, 1982 Supplement 2 · Efficacy
  • Sep 17, 1976 Original approval · Type 2 - New Active Ingredient · priority review
1 products under this application
  • HIBICLENS · CHLORHEXIDINE GLUCONATE 4% · SOLUTION, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.

All 551 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,922
  • joint swelling1,726
  • rash1,724
  • hypersensitivity1,677
  • impaired healing1,635
  • pain1,631
  • folliculitis1,621
  • weight increased1,613
  • stomatitis1,569
  • arthralgia1,568
  • lower respiratory tract infection1,543
  • off label use1,539

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200430
200522
200630
200740
200894
2009104
2010160
2011165
2012180
201377
201492
2015149
2016281
2017290
2018332
2019351
2020439
2021702
2022625
2023536
20241,343
20251,570
2026574

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 573 on PubMed

Sponsor: Molnlycke Hlth

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.